SECsense Logo

Citius Oncology, Inc. 8-K Report: Key Updates for Investors - January 2025

$CTOR
Form 8-K
Filed on: 2025-01-07
Source
Citius Oncology, Inc. 8-K Report: Key Updates for Investors - January 2025

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: Citius Oncology, Inc.
  • CIK: 0001851484
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-41534
  • Tax ID: 99-4362660
  • Address: 11 Commerce Drive, 1st Floor, Cranford, NJ 07016
  • Phone Number: 908-967-6677
  1. Financial Reporting Period:
  • Report Date: January 7, 2025
  • The report is a Form 8-K, indicating it is a current report used to disclose major events that shareholders should know about.
  1. Stock Information:
  • Common Stock Ticker Symbol: CTOR
  • Exchange: NASDAQ
  1. Units of Reporting:
  • The financial information is reported in U.S. Dollars (USD) and shares.
  • The report includes a unit denominator that appears to be shares, which indicates that the financial metrics may involve a per-share calculation or valuation.
  1. Context and Structure:
  • The XBRL (eXtensible Business Reporting Language) format suggests that this filing includes structured financial data, allowing for easier analysis and comparison.
  • The schema reference indicates compliance with specific reporting standards.

Insights:

  • The filing indicates that Citius Oncology, Inc. is actively reporting significant happenings relevant to its investors, as is required by the SEC for publicly traded companies.
  • The fact that this is a Form 8-K is significant, as it typically includes information on events like acquisitions, changes in management, or other critical corporate events.
  • The use of XBRL format enhances the transparency and accessibility of the company's financial data for analysts and investors.
  • The presence of a specific reporting date suggests that the information is timely and may pertain to recent developments in the company or its operations.

Overall, this section of the financial report provides essential details about Citius Oncology, Inc., its reporting obligations, and the context for the financial data that may be presented in the complete filing.